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Abstract: Cystic fibrosis (CF) is the most common life-limiting inherited disease in  Caucasian 
populations. The main cause of death in CF patients is respiratory failure resulting from chronic 
pulmonary infection. Pseudomonas aeruginosa is the most prevalent organism in the airway 
colonization of CF patients, and its persistence in the airways has been related to greater 
 morbidity with a more rapid deterioration in lung function. P. aeruginosa has enormous genetic 
and metabolic flexibility that allows it to adapt and persist within the airways of CF patients, and 
it has the ability to easily acquire antimicrobial resistance. For these reasons, the  management 
of infections and chronic colonization by P. aeruginosa remains a challenge for physicians. 
This article reviews the current and future antibacterial chemotherapy options for respiratory 
pseudomonal infection in CF patients.
Keywords: cystic fibrosis, Pseudomonas aeruginosa, respiratory infection, antimicrobial 
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Introduction
Cystic fibrosis (CF) is a multisystem disorder caused by mutations on the cystic 
transmembrane conductance regulator (CFTR) gene located on chromosome 7.1 It is 
the most common life-limiting, autosomal recessively inherited disease in Caucasian 
populations. Although this is a multisystem disorder, pulmonary disease remains the 
leading cause of morbidity and mortality in patients with CF. The primary cause of 
death in these patients is respiratory failure resulting from chronic pulmonary infection.2 
Early infections in CF airways are most frequently caused by Staphylococcus aureus 
and Haemophilus influenzae, organisms that may be seen in other young children 
with chronic illnesses and in adults with non-CF bronchiectasis. Other organisms 
that are identified later in the course of CF airways disease include Burkholderia 
 cepacia, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, fungi including 
 Aspergillus, and nontuberculous mycobacteria. Nevertheless, CF airway is particularly 
susceptible to Pseudomonas aeruginosa, which is considered the most important 
pathogen in this chronic disease. The prevalence of P. aeruginosa infection increases 
as patients age, such that .70% of adults are chronically infected.3 P. aeruginosa is 
extremely difficult to eradicate once established in the CF airway. This phenomenon 
is due to poor penetration of antibiotics into purulent airway secretions, native or 
acquired antibiotic resistance, CF-related defects in mucosal defenses, or biofilms 
produced by the bacteria, which interfere with phagocytic killing. Although chronic 
infection has been referred as ‘airway colonization’, the presence of these bacteria is 
not benign. Epidemiologic studies show that chronic infection with P. aeruginosa is 
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an independent risk factor for accelerated loss of pulmonary 
function and decreased survival.4,5
The quality of life and life expectancy of CF patients 
have improved considerably as a result of the control of 
bronchopulmonary bacterial colonization and exacerbations.6 
Nevertheless, because of the lack of scientific evidence, these 
issues remain a challenge for physicians.
This article reviews the current and future antibacterial 
chemotherapy options for respiratory pseudomonal infection 
in CF patients.
Epidemiology and pathogenesis  
of P. aeruginosa
P. aeruginosa is a usually noncapsulate, nonsporing, and 
nonfermenting Gram-negative bacillus that is common in the 
environment, especially in water. The ability of P. aeruginosa 
to persist and multiply in moist environments (soil detritus 
and equipment such as humidifiers in hospital wards, urinary 
catheters, bathroom sinks, and kitchens) is of particular 
importance in crossinfection.7
Currently, P. aeruginosa is a pathogen of great relevance 
in infectious disease for different reasons: a) reservoirs for 
infection can develop, especially in intensive care units, often 
associated with water in sinks or respiratory equipment; 
b) the microorganism displays a predilection for infecting 
immunocompromised hosts (including burn patients) whose 
proportion is increasing in our hospitals and society; c) it is 
the most serious pathogen in ventilator-associated pneumonia 
and one of the most common in other nosocomial infections; 
and d) there is an increase in occurrence of P. aeruginosa 
strains with resistance to multiple antibiotics.8
P. aeruginosa is the most common cause of respiratory 
failure in CF and is responsible for the death of the  majority 
of these patients. Acquisition of P. aeruginosa begins early in 
childhood.9
It is believed that the bacterium is initially acquired 
from environmental sources, but patient-to-patient spread 
has also been described.10,11 In patients with CF, prevalence 
of pseudomonal pneumonia ranges from 21% in those 
younger than 1 year to .80% in those older than 19 years. 
The increasing longevity of patients with CF has created a 
significant shift in the proportion of adult patients with CF; 
their proportion has increased fourfold, from 8% in 1969 to 
33% in 1990.12
Impaired mucociliary clearance and bronchiectatic changes 
to the airways predispose patients with CF to lower respiratory 
tract bacterial colonization and recurrent  infections, especially 
by P. aeruginosa.13 P. aeruginosa has enormous genetic and 
metabolic flexibility that allows it to adapt to the milieu and 
persist within the airways of CF patients. The genotypes 
and phenotypes of the strains present in late stages of the 
disease differ substantially from those that initially colonize 
the lungs.14 Initial isolates of this microorganism are often 
nonmucoid strains. As lung disease  progresses, mutants 
with a mucoid phenotype owing to  alginate overexpression 
are selected.  Exopolysaccharide  production is increased in 
response to the hypoxic  environment of the mucus that cov-
ers the airway surface and contributes to highly structured 
biofilm formation.15 Alginate protects P. aeruginosa from 
being killed by immune cells because it provides a physical 
barrier for the bacteria and it scavenges free radicals 
released by neutrophils and macrophages.16 These mucoid 
strains are associated with deterioration in cough scores, 
chest X-ray scores, and pulmonary function.17 Deteriora-
tion in lung function is related to anatomical changes in the 
airways caused by enhanced and persistent inflammation. 
Patients with CF have an increased number of neutrophils 
and levels of IL-8 in bronchoalveolar lavage (BAL) fluid and 
reduced production of IL-10, an  anti-inflammatory cytokine, 
as compared with non-CF patients. Accordingly, they have an 
abnormally intense and prolonged inflammatory response to 
infections and the products of this excessive inflammation, 
which include neutrophil elastase and DNA fragments from 
 apoptotic neutrophils, contribute to anatomic damage.6
The genetic and metabolic flexibility of P. aeruginosa 
also contributes to its ability to develop antimicrobial 
 resistance, making eradication of P. aeruginosa infec-
tion almost impossible. One of the major mechanisms of 
resistance to many antibiotics is the expression of multiple 
efflux pump systems.18,19 In addition, P. aeruginosa has the 
ability to acquire antimicrobial resistance genes encoded in 
plasmids and transposons through horizontal transfer from 
other Gram-negative bacteria.20
Clinical assessment of pulmonary 
health status
Routine imaging and laboratory evaluations are critical to 
assessing pulmonary status in CF patients. These studies 
are used to monitor disease progression and response to 
 therapeutic interventions and evaluate exacerbations.
Chest X-rays are helpful for defining disease  progression 
(detection of hyperinflation with flattened diaphragms, 
 retrosternal lucency, nodular opacities due to mucus  plugging, 
and cystic changes due to bronchiectasis). Chest X-ray scores 
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have been developed for assessing disease progression,21,22 
but have never been used widely in clinical practice.6
High-resolution computerized tomography (HRCT) 
is more sensitive and specific than chest radiographs in 
 identifying changes in early CF lung disease (airway wall 
thickening, gas trapping) and is particularly useful in 
 identifying localized areas of bronchiectasis and  parenchymal 
abnormalities.23 Accordingly, HRCT is being used to 
 document localized disease and respond to antibiotic therapy 
during acute exacerbations.24 The cost and radiation exposure 
are some of the reasons that explain the lack of consensus 
guidelines for use of HRCT in CF care.25
The main measure of pulmonary status in individuals 
with CF is pulmonary function testing with spirometry or 
plethysmography. Lung function measurements are useful 
in documenting stability or progression of airway obstruc-
tion and air trapping. These tests are also useful to detect 
acute changes associated with pulmonary exacerbations 
and response to therapy.6 The earliest spirometric evidence 
of obstructive disease is a decrease in expiratory flows 
at low volumes such as forced expiratory flow between 
25% and 75%, while the most widely used parameter to 
evaluate lung status is forced expiratory volume in 1 second 
(FEV
1
) because of the universal accessibility of spirometric 
 equipment,  standardized criteria for performance, availability 
of  reference values, and reproducibility.26,27
In daily practice, FEV
1
 has two important functions: 
1) it is the primary marker for disease progression identi-
fied in numerous epidemiologic studies to predict decline in 
health status and mortality28 and 2) it is the primary outcome 
measure used for defining clinical efficacy for therapeutic 
modalities in CF.29
Microbiological assessment  
of P. aeruginosa
Microbiological studies are mostly performed using sputum 
samples. However, collecting this specimen may be difficult 
in the younger patients. Oropharyngeal cultures have been 
well studied in this situation but their value is inferior to that 
of sputum because of their lower sensitivity.30
BAL is a more sensitive measure for diagnosing infection, 
and it is also more invasive. This test should be reserved for 
assessing patients unresponsive to antimicrobial therapy or 
those with progressive disease.31 Hypertonic saline induction 
of sputum has been reported to be a good surrogate for lower 
airway sampling in both adult and older pediatric patients 
with CF.32
In patients with an early diagnosis of CF, it is essential to 
undertake continuous microbiological monitoring to detect 
incipient colonization by P. aeruginosa. In this stage, optimal 
frequency for performing sputum cultures is controversial. 
A monthly, or at least trimonthly, culture is advisable for 
patients without evidence of P. aeruginosa colonization in 
order to detect the initial isolation and initiate early  treatment. 
From other patients, cultures should be taken whenever 
 exacerbations present or, at least, every 2–3 months in periods 
with clinical stability.33,34
All P. aeruginosa morphotypes isolated in the culture 
should be tested for susceptibility to antimicrobial agents. 
There is consensus that incubation of susceptibility tests 
should be for at least 24 h to facilitate growth of mucoid and 
small-colony variants. The precise method to evaluate this 
issue remains controversial but it should permit calculation 
of the MIC.35,36
Interaction patterns of P. aeruginosa 
with lungs: colonization versus 
infection
‘Colonization’ refers to bacterial development on a surface 
without harmful effects while ‘infection’ indicates a pathogenic 
effect resulting from microbial invasion of the tissues.5
In CF patients, pulmonary infections are associated 
with symptoms and clinical signs of respiratory illness: 
increased cough, increased sputum production, decreased 
exercise  tolerance or increased dyspnea with exertion, 
increased fatigue, decreased appetite, increased respira-
tory rate or  dyspnea at rest, change in sputum appearance, 
fever, and increased nasal congestion or drainage. These 
clinical  situations tend to correspond to clinical respiratory 
 exacerbations of a chronic bacterial colonization.37
Classically, in CF patients the term ‘colonization’ has 
been used to describe a clinical situation without  symptoms 
or signs consistent with pulmonary infection but with 
 persistence of the same microorganisms in successive 
 sputum cultures. In case of P. aeruginosa, its persistence 
in the  airways has been related to greater morbidity with a 
more rapid deterioration in lung function.4 For this reason, it 
could be more accurate to refer to this situation in terms of 
‘pathogenic colonization’ or ‘chronic infection’.34
Different microbiological patterns and criteria in 
 pulmonary P. aeruginosa colonization/infection in CF 
patients are summarized in Table 1. This classification 
is clinically important because each situation should be 
addressed differentially from the therapeutic viewpoint.
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Antimicrobial treatment in clinical 
practice
Special issues in CF pharmacokinetics
CF patients generally have a larger volume of  distribution 
(V
d
) for many antibiotics, including β-lactam agents and 
 aminoglycosides, due to their lower fat stores and an increased 
ratio of lean body mass to total body mass  compared with 
the non-CF population. Consequently, larger doses of anti-
bacterial agents must be given to attain the same serum 
concentration as individuals with a larger adipose mass.38,39 
Enhanced total body clearance of antibiotics has also been 
observed within the CF population. Increased renal clear-
ance, decreased protein binding, extrarenal elimination, and 
increased metabolism have been proposed as possible reasons 
for this increased clearance although the exact mechanism 
has not been determined. There are fewer pharmacokinetic 
deviations for fluoroquinolones; however, higher doses are 
typically needed for activity against CF pathogens.38
The increased V
d
 and enhanced clearance of antibiotics, 
combined with the difficulty of lung tissue penetration and 
P. aeruginosa antimicrobial resistance, make antibiotic dosing 
to get therapeutic drug concentrations a real challenge in CF 
patients. Aminoglycosides have been widely studied trying 
to optimize their therapeutic concentrations and minimize 
 toxicity. The bactericidal efficacy of this antibiotic family is 
peak dependent (postdose drug concentration) while the main 
adverse effects such as nephrotoxicity are trough dependent 
(predose drug concentration).40 Historically, aminoglycosides 
have been administered three times daily in CF patients with 
normal renal function; however, recent strategies have included 
once-daily dosing regimens in an effort to maximize peak and 
minimize trough concentrations.41,42 A meta-analysis published 
in 2010 concluded that once and three times daily aminoglyco-
side antibiotics appear to be equally effective in the treatment 
of pulmonary exacerbations of CF patients with evidence of 
less nephrotoxicity in children in the once-daily regimen.43
Table 1 Microbiological patterns and criteria in pulmonary Pseudomonas aeruginosa colonization/infection in cystic fibrosis patients
Infection/colonization Definition Microbiological criteria Comments
I.  Initial colonization  
(first colonization event  
or pioneer colonization)
Detection of the first positive  
P. aeruginosa culture in the  
bronchial tree. No clinical  
symptoms
First positive P. aeruginosa culture A positive culture following  
1 year of negative cultures after  
finishing treatment is considered  
as a new initial colonization.  
The strains are usually nonmucoid 
colonies, with little diversity in  
morphotypes or antimicrobial  
susceptibilities
II.  Sporadic or  
intermittent colonization
Intermittent presence of positive  
and negative P. aeruginosa  
cultures in consecutive samples  
after initial colonization.  
No signs of infection
Detection, within a period of 6 months  
of the initial colonization, of a positive  
P. aeruginosa culture among at least  
three cultures, with at least 1 month  
between each positive culture
Possible recovery of strains  
with mucoid colonies and other  
colonial morphotypes
III.  Colonization with  
bronchopulmonary  
infection
Initial or sporadic  
colonization with  
presentation of clinical signs  
of infection
As for initial or sporadic colonization In patients without  
microbiological specimens, the  
appearance or increase of  
antibodies in two successive  
blood samples, with at least  
3 months between each sample,  
can be used as a diagnostic  
criterion
Iv. Chronic colonization Persistent positive P. aeruginosa  
cultures without new clinical  
signs of infection
Detection within a period of 6 months  
of a minimum of three positive  
P. aeruginosa cultures, with at least  
1 month between the positive cultures
Usually produced by strains  
with mucoid colonies and other  
colonial morphotypes. This is  
the common pattern during  
advanced periods of the disease
v.  Chronic  
bronchopulmonary  
infection (exacerbation)
Presentation of clinical signs  
of infection during the course  
of a chronic colonization
As for chronic colonization In patients with microbiological  
specimens, an increase of  
antibodies in two successive  
blood samples can be used as a  
diagnostic criterion
Copyright © 2005, wiley. Adapted with permission from Cantón R, Cobos N, de Gracia J, et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection 
by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect. 2005;11(9):690–703.
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Commonly used antimicrobial agents for P. aeruginosa 
infections are shown in Table 2.
eradication strategies to prevent chronic 
P. aeruginosa infection
Active treatment of f irst isolation of P. aeruginosa is 
 critical in order to delay or prevent chronic infection state 
and its clinical consequences.44–47 The authors of a recent 
 meta-analysis48 conclude that treating of early infection 
results in microbiological eradication of P. aeruginosa for 
several months. There is insufficient evidence to state which 
antibiotics strategy should be used for the eradication of early 
P. aeruginosa infection because of the enormous heterogene-
ity in regimens administered by clinicians from different CF 
specialized centers.45,49,50 These regimens most often include 
the combination of oral fluoroquinolones and/or intravenous 
antipseudomonal agents with a prolonged course of inhaled 
tobramycin or colistin. In our setting, stable patients (without 
respiratory symptoms) usually receive oral ciprofloxacin 
(30–40 mg/kg/day) divided into two doses (maximum 2 g/
day) for 3–4 weeks combined with inhaled tobramycin or 
colistin. If sputum culture is negative 1 month after the start 
of treatment, the inhaled therapy is maintained for at least 
6 months to avoid early recurrence; whereas, if culture is posi-
tive, the treatment cycle is repeated. If the sputum collected 
at the end of the second cycle is still positive, the patient is 
considered chronically colonized.34 For positive P. aeruginosa 
cultures, an antibiogram should be performed and the anti-
microbial therapy should be adapted accordingly. Despite 
the high prevalence of  susceptibility to antipseudomonal 
antibiotics found in P. aeruginosa  associated with initial 
infections, an antibiogram should also be performed in 
this situation because susceptibility in early isolates cannot 
be presumed.51 The US multicenter Early Pseudomonas 
Infection Control (EPIC) study is currently in process. This 
investigation is evaluating different strategies for early P. 
aeruginosa eradication and observing the natural history of 
its acquisition in early childhood.
Maintenance after development  
of chronic P. aeruginosa infection
Both oral and inhaled antibiotics offer potential benefits to 
patients with chronic respiratory P. aeruginosa infection. 
A large placebo-controlled trial assessing the use of inhaled 
tobramycin given twice daily on an alternating month basis 
for 6 months was published in 1999 and shows clear benefit to 
the use of this regimen as a chronic maintenance therapy for 
patients colonized with P. aeruginosa.29 Pulmonary function 
was improved and the need for hospitalization was decreased 
among patients in the inhaled therapy group compared with 
placebo. Long-term follow-up of patients using inhaled 
tobramycin has demonstrated efficacy and no significant side 
effects.52 In recently published US guidelines, the chronic 
use of inhaled tobramycin is recommended for patients aged 
6 years and older with P. aeruginosa persistently present in 
cultures of the airways in order to improve lung function and 
reduce exacerbations.53
Nebulized colistin is also commonly used as chronic 
maintenance treatment for P. aeruginosa colonization. One 
short-term trial of 1 month, with 115 patients included, 
Table 2 Antibiotics for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis
Antibiotic Pediatric dose Adult dose
Oral ciprofloxacin 10–20 mg/kg twice a day 500–750 mg twice a day
Tobramycin via inhalation 300 mg by nebulizer, twice a daya 300 mg by nebulizer, twice a day
Colistin via inhalation 75–150 mg by nebulizer, twice a dayb 75–150 mg by nebulizer, twice a day
Ciprofloxacin 10 mg/kg intravenously every 8–12 h 400 mg intravenously every 12 h
Ceftazidime 50–100 mg/kg intravenously every 8 h 2 g intravenously every 8 h
Cefepime 50 mg/kg intravenously every 8 h 2 g intravenously every 8 h
Piperacillin–tazobactam 90 mg/kg intravenously every 6 h 4.5 g intravenously every 6–8 h
Aztreonam 50 mg/kg intravenously every 8 h 2 g intravenously every 8 h
Imipenem 15–25 mg/kg intravenously every 6 h 500 mg to 1 g intravenously every 6 h
Meropenem 40 mg/kg intravenously every 8 h 1–2 g intravenously every 8 h
Doripenem 10–15 mg/kg intravenously every 8 h 500 mg intravenously every 8 h
Tobramycin 5–10 mg/kg intravenously every 24 hc 7 mg/kg intravenously every 24 hc
Amikacin 20–30 mg/kg intravenously every 24 hd 15–20 mg/kg intravenously every 24 hd
Colistin 1.5–2 mg/kg intravenously every 8 he 80–160 mg intravenously every 8 hf
Notes: aIn patients ,6 years, inhaled tobramycin, 80 mg/12 h; bDose expressed as milligrams of colistimethate; 1 mg of colistimethate = 12,500 IU. The recommended 
dose of 75–150 mg/12 h is approximately equal to 1–2 million IU, twice a day; cDosage should be adjusted to serum trough concentration ,1 μg/mL; dDosage should be 
adjusted to serum trough concentration ,4–5 μg/mL; eDose expressed as milligrams of colistimethate for patients ,60 kg. Pediatric dose: 18,000–24,000 IU/kg every 8 h; 
fDose expressed as milligrams of colistimethate for patients $60 kg. Adults dose: 1–2 million IU every 8 h.
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 compared tobramycin and colistin and showed a trend 
toward greater improvement in FEV
1
 in the tobramycin 
group.54 However, the use of one agent over the other was not 
favored in a large meta-analysis.55 In this meta-analysis, the 
incidence of antibiotic resistance with inhaled maintenance 
therapy was assessed and was of low-frequency occurrence. 
 Nevertheless, patients with highly resistant pathogens 
detected in sputum cultures may still derive clinical benefits 
from aerosolized drugs like tobramycin.56 This should be due 
to the  pharmacodynamic benefits of inhaled antibiotics with 
high concentrations attained in the site of infection and low 
risk of systemic toxicity.57 Despite this low risk of systemic 
toxicity, it has been found that after inhalation of aminogly-
cosides significant serum drug levels can appear.58–60 This fact 
should be considered in patients with baseline renal failure 
or in patients receiving other nephrotoxic agents.
Other inhaled agents such as aztreonam,  fluoroquinolones, 
and amikacin are in developmental stages and hold potential 
as alternative agents for chronic maintenance therapy.61 
Aztreonam lysine for inhalation solution has been studied 
in two phase III, randomized, placebo-controlled trials in 
CF population, and it has shown improvement in respiratory 
symptoms, pulmonary function, and sputum P. aeruginosa 
density in the treated patients.62,63
There is growing interest in evaluating combination 
therapies to combat P. aeruginosa biofilms in the air-
ways of CF patients. Colistin–tobramycin combination 
has been assessed in biofilm models in vitro and in rat 
lungs, showing better results than in those cases receiving 
single antibiotics. In five CF patients, inhaled colistin–
tobramycin was well tolerated and resulted in a mean 
decrease of log(10) cfu of P. aeruginosa per milliliter 
of sputum.64
Oral antipseudomonal antibiotics could be a  comfortable 
alternative to nebulized therapy for maintenance of  long-term 
treatment. Fluoroquinolones have several characteristics 
that have made them appealing for oral maintenance ther-
apy: broad spectrum antibacterial activity with excellent 
 bactericidal activity against most P. aeruginosa strains, excel-
lent oral absorption, and bioavailability in airway secretions.65 
Despite ciprofloxacin monotherapy having demonstrated 
comparable results with intravenous drugs treating mild 
exacerbations, the emergence of  fluoroquinolone-resistant P. 
aeruginosa in treatments for more than 3–4 weeks has been 
observed.66 Thus, prolonged treatment with this antibiotics 
class is discouraged.6
Use of azithromycin, 250 or 500 mg three times 
weekly, has been recommended for patients with chronic 
 P.  aeruginosa colonization.53,67 As a bacteriostatic effect of 
macrolides against P. aeruginosa has not been reported, it has 
been suggested that an immunomodulating activity is respon-
sible for the observed improvement in CF patients.68 This 
anti-inflammatory effect has been demonstrated in in vitro 
models and in mice.69,70 A recently published meta-analysis 
demonstrated that the regular use of oral azithromycin shows 
a small, but significant, improvement in respiratory function 
at the 1- and 6-month points.71 Some studies also suggest a 
decrease in the number of exacerbations,67,72,73 and only one 
reported a significant increase in mild adverse events like 
nausea, diarrhea, and wheezing.67
Treatment of patients with exacerbations
The aim of exacerbations treatment is to restore the  baseline 
lung function present before the onset of  respiratory 
 symptoms. In this situation, the antimicrobial therapy is 
targeted to decrease the bacterial inoculum in the spu-
tum because the eradication of the pathogen is virtually 
impossible.74,75 Moderate and severe exacerbations should 
be treated with  intravenous agents while oral antibiotics 
(basically  ciprofloxacin) are recommended for patients with 
mild respiratory worsening.34,76
The choice of empiric antimicrobial agents is usually 
based on finding two drugs with differing mechanisms of 
action which demonstrate in vitro efficacy on conventional 
drug susceptibility testing of previous sputum cultures 
and secondly, modifying these agents according to the 
 susceptibility testing of current samples.
Common intravenous regimens generally include 
the use of an antipseudomonal β-lactam (piperacillin– 
tazobactam, ceftazidime, cefepime, meropenem, imipenem, 
or  aztreonam), combined with an aminoglycoside (amikacin 
much more widely used than gentamicin or tobramycin). The 
standard approach to antibiotic treatment of exacerbations 
due to P. aeruginosa has been to use two antipseudomonal 
drugs to enhance activity and reduce selection of resistant 
organisms, but this combination therapy has not demon-
strated a clear superiority over monotherapy.77 Use of a 
single antibiotic could result in reduced toxicity as well as 
cost, and these are important issues for patients who will be 
treated multiple times throughout life.78 In a large systematic 
review, the overall results showed that there was no significant 
 difference between monotherapy and combination therapy in 
terms of clinical outcome measures, such as lung function and 
symptoms scores, or in terms of bacteriological outcomes.79 
However, there was considerable heterogeneity among the 
eight trials included in the review, and their methodological 
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quality was poor. Consequently, adequate meta-analyses for 
most outcome measures could not be performed.
Standard treatment courses for exacerbations generally last 
for 14–21 days, but there are no clear guidelines or evidence 
on the optimum duration. Shorter courses should improve 
quality of life and compliance, result in reduced incidence of 
drug reactions, and be less costly. However, this may not be 
sufficient to clear a chest infection and may result in an early 
recurrence of an exacerbation.80 Treatment can be administered 
at the hospital setting or at home if clinically and socially 
possible. Domiciliary intravenous therapy is becoming more 
common as it reduces the number of hospital admissions, 
entails fewer investigations, reduces social disruptions, and 
provides to some patients a better quality of life.81,82
An important tool that should complement the antibiotic 
treatment in respiratory exacerbations is the airway clearance 
therapy by chest physiotherapy (postural drainage with chest 
percussion in several anatomic positions to favor gravita-
tional clearance of secretions of all lobes of the lung).6,83
Management of infections due to multiple 
drug resistant P. aeruginosa
Drug resistance is an inevitable problem in CF-related 
 infections linked to the inability to eradicate chronically infect-
ing pathogens and the requirement for repeated courses of anti-
microbials during pulmonary exacerbations. In P. aeruginosa, 
multiple drug resistance (MDR) is defined as resistance to all 
agents in two or more classes of standard  antibiotics, and its 
prevalence has been reported at 9.6%–19.2% of isolates.84,85 
MDR P. aeruginosa has been associated with increased num-
ber of exacerbations, accelerated rate of lung function decline, 
and increased risk of death.86
When P. aeruginosa loses susceptibility to the 
 antipseudomonal antibiotics commonly used (fluoroquino-
lones and β-lactams), some old and new antibiotics must be 
considered.
Colistin, a molecule discovered more than 50 years 
ago, was discontinued because of a high incidence of 
 nephrotoxicity.87 This drug has received renewed interest 
because of its mode of action in disrupting the cytoplasmic 
membrane of Gram-negative bacteria.88 This mechanism pro-
tects colistin from crossresistance from other  antipseudomonal 
agents and is unlikely to lead to a rapid selection of new 
resistance.89 The drug displays a concentration-dependent 
bactericidal activity90 and has recently been reintroduced 
for the  management of pulmonary infections in CF patients, 
either by intravenous route or in the form of an aerosol, with 
lower rates of toxicity than reported previously.91,92
Doripenem is a recently introduced carbapenem that 
offers potentially enhanced anti-Gram-negative activity 
 relative to previously available drugs of this class but does 
not expand its spectrum of activity.93 The MIC
90
 of doripenem 
is generally two-fold to four-fold lower than the correspond-
ing values for meropenem and imipenem and, talking about 
MDR P. aeruginosa strains, this carbapenem remains active 
against 32% of CF isolates nonsusceptible to imipenem and 
8.5% of isolates nonsusceptible to meropenem.94 As other 
β-lactams, the pharmacodynamic parameter predictive of in 
vivo efficacy of doripenem is a percentage of the time over 
required MIC (%TMIC) (with 30% generally considered bac-
teriostatic and $50% considered bactericidal).95 In modeling 
studies, using doripenem 500 mg infused over 1 h, %TMIC 
was 45% for a target of 2 mg/L, but when the infusion was 
extended to 4 h, this index increased to 68%.96 Using 1 g 
of doripenem infused over 4 h, %TMIC increased to 81%. 
According to these results, because of its good tolerability 
and the absence of significant drug interactions,97 this strategy 
using high doses and extended infusions of doripenem should 
be assessed in upcoming clinical trials.
Ceftobiprole is a new broad-spectrum cephalosporin with 
activity against most Gram-positive organisms, including 
methicillin-resistant Staphylococcus aureus, and similar 
Gram-negative spectrum to that of cefepime, including 
P. aeruginosa. It is not active against ceftazidime-/cefepime-
resistant P. aeurginosa, so it does not provide benefits for 
treating MDR pathogens.98
There are methods of testing the susceptibility of bacteria 
to combinations of antibiotics. Combination antimicrobial 
susceptibility testing assesses the efficacy of drug combi-
nations including two or three antibiotics in vitro and can 
often demonstrate antimicrobial efficacy against bacterial 
isolates even when individual antibiotics have little or no 
effect. Therefore, choosing antibiotics based on this synergy 
testing could potentially improve response to treatment 
in CF patients with acute exacerbation. There is only one 
randomized controlled trial comparing this strategy with 
conventional procedures, and its data did not provide evi-
dence that combination susceptibility testing was superior 
to routine testing.99,100
Future therapies
Most upcoming antimicrobial drugs are new derivatives of 
existing families with similar mode of action. Therefore, 
they probably will not solve the problem of emerging mul-
tiresistant pathogens. Alternative antimicrobial approaches 
are gaining more interest to address this problem. Regarding 
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 prophylactic measures, there have been many approaches 
in the development of vaccines for the prevention of 
P. aeruginosa infection, but early trials produced disappoint-
ing results.101 However, a study showed that regular vacci-
nation for a period of 10 years with a polyvalent conjugate 
 vaccine reduced the incidence of chronic infection with P. 
aeruginosa and was associated with better preservation of 
lung function, particularly in older patients.102 With current 
information, vaccines against P. aeruginosa cannot be rec-
ommended according to a recently published review,103 so 
further  investigations are required.
The main defense mechanisms against Gram-negative 
bacterial infections are complement-activated killing and 
complement-mediated opsonophagocytosis. Polysaccharides 
such as lipopolysaccharides are T cell–independent antigens 
that trigger the innate immune system via the stimulation 
of pattern recognition receptors (eg, Toll-like receptor 4). 
Antibodies induced in response to them are mostly of the 
immunoglobulin M (IgM) isotype. IgM antibodies have sev-
eral favorable properties that support their use as therapeutic 
tools: their pentameric form provides 10 antigen binding 
sites, they bind antigens with high avidity, and IgM antibod-
ies are very effective complement activators.104
Combined treatment with IgM monoclonal antibodies 
(MAbs) and antibiotics could lead to a more rapid resolu-
tion of infections, resulting in shorter stays in intensive care 
units as well as reductions of morbidity, mortality, and health 
care costs. Human-obtained MAb against P. aeruginosa 
was assessed in a murine burn wound sepsis model, where 
full protection of animals against lethal challenges with 
P. aeruginosa was achieved at very low doses. Also, an acute 
lung infection model using mice showed protection against 
local respiratory infections.
A study demonstrated the safety of this IgM MAb in 
healthy volunteers,105 and these results warrant further testing 
of this strategy in infected patients in order to confirm the 
therapeutic potential of this compound.
Phage therapy is the therapeutic use of bacteriophages 
to treat pathogenic bacterial infections. Bacteriophages are 
viruses which specifically and uniquely seek out and destroy 
bacteria. They do not attack mammalian cells and exist as 
partners in microbiological ecosystems in the human body 
and in the environment. Although phage therapy has been 
known for over 90 years and in spite of the continued use of 
this technique in eastern Europe,106 it has attracted world-
wide renewed interest as an alternative or complement to 
conventional antibiotic therapy due to emergence of 
multidrug-resistant pathogens. This approach has demonstrated 
its efficacy in mouse burn wound P. aeruginosa infection 
model107 and in mice gut-derived P. aeruginosa sepsis model.108 
The first controlled clinical trial of a therapeutic bacteriophage 
preparation in humans showed efficacy and safety in chronic 
otitis due to multidrug-resistant P. aeruginosa.109
This form of biological therapy has considerable promise, 
and it should be the subject of for further investigations.
Finally, therapies directed against virulence factors of P. 
aeruginosa (biofilm formation, quorum sensing, flagella, or 
type III secretion) have been the focus on much recent inves-
tigation. These promising translational strategies may lead to 
the development of adjunctive therapies capable of improving 
outcomes.110
Disclosure
The authors have no financial interest in this article.
References
 1. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the 
cystic fibrosis gene: chromosome walking and jumping. Science. 
1989;245(4922):1059–1065.
 2. FitzSimmons SC. The changing epidemiology of cystic fibrosis. 
J Pediatr. 1993;122(1):1–9.
 3. Cystic Fibrosis Foundation Patient Registry: Annual Data Report 2008. 
Bethesda, MD: Cystic Fibrosis Foundation; 2009.
 4. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. 
Pseudomonas aeruginosa and other predictors of mortality and 
morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 
2002;34(2):91–100.
 5. Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary 
 infection, inflammation, and clinical outcomes in infants with cystic 
fibrosis. Pediatr Pulmonol. 2001;32(5):356–366.
 6. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management 
of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 
2003;168(8):918–951.
 7. Döring G, Jansen S, Noll H, et al. Distribution and transmission of 
Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. 
Pediatr Pulmonol. 1996;21(2):90–100.
 8. National Nosocomial Infections Surveillance System. National 
 Nosocomial Infections Surveillance (NNIS) System Report, data 
 summary from 1992 Jan through 2004 Jun, issued 2004 Oct. Am J 
Infect Control. 2004;32(8):470–485.
 9. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of 
mucoid Pseudomonas aeruginosa infection and lung disease  progression 
in children with cystic fibrosis. JAMA. 2005;293(5):581–588.
 10. Kosorok MR, Jalaluddin M, Farrell PM, et al. Comprehensive analysis 
of risk factors for acquisition of Pseudomonas aeruginosa in young 
children with cystic fibrosis. Pediatr Pulmonol. 1998;26(2):81–88.
 11. Renders NH, Sijmons MA, van Belkum A, Overbeek SE, Mouton JW, 
Verbrugh HA. Exchange of Pseudomonas aeruginosa strains among 
cystic fibrosis siblings. Res Microbiol. 1997;148(5):447–454.
 12. Chen SSP, Rudoy R. Pseudomonas infection. Emedicine (Medscape). 
Available from: http://emedicine.medscape.com/article/970904-
overview. Updated 2010 Feb 25. Accessed May 20 2010.
 13. Govan JR, Brown AR, Jones AM. Evolving epidemiology of 
 Pseudomonas aeruginosa and the Burkholderia cepacia complex in 
cystic fibrosis lung infection. Future Microbiol. 2007;2:153–164.
 14. Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by  Pseudomonas 
aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci 
U S A. 2006;103(22):8487–8492.
Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
39
Management of refractory P. aeruginosa infection in CF
 15. Ramsey DM, Wozniak DJ. Understanding the control of  Pseudomonas 
aeruginosa alginate synthesis and the prospects for manage-
ment of chronic infections in cystic fibrosis. Mol Microbiol. 2005; 
56(2):309–322.
 16. Song Z, Wu H, Ciofu O, et al. Pseudomonas aeruginosa alginate is 
refractory to Th1 immune response and impedes host immune clear-
ance in a mouse model of acute lung infection. J Med Microbiol. 
2003;52(Pt 9):731–740.
 17. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid 
Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev. 
1996;60(3):539–574.
 18. Poole K, Srikumar R. Multidrug efflux in Pseudomonas aeruginosa: 
components, mechanisms and clinical significance. Curr Top Med 
Chem. 2001;1(1):59–71.
 19. Poole K, Krebes K, McNally C, Neshat S. Multiple antibiotic resistance 
in Pseudomonas aeruginosa: evidence for involvement of an efflux 
operon. J Bacteriol. 1993;175(22):7363–7372.
 20. Weldhagen GF, Poirel L, Nordmann P. Ambler class A extended-
spectrum beta-lactamases in Pseudomonas aeruginosa: novel 
developments and clinical impact. Antimicrob Agents Chemother. 
2003;47(8):2385–2392.
 21. Brasfield D, Hicks G, Soong S, Tiller RE. The chest roentgenogram 
in cystic fibrosis: a new scoring system. Pediatrics. 1979;63(1): 
24–29.
 22. Weatherly MR, Palmer CG, Peters ME, et al. Wisconsin cystic 
fibrosis chest radiograph scoring system. Pediatrics. 1993;91(2): 
488–495.
 23. Shah RM, Sexauer W, Ostrum BJ, Fiel SB, Friedman AC. 
 High-resolution CT in the acute exacerbation of cystic fibrosis: 
 evaluation of acute findings, reversibility of those findings, and clinical 
correlation. AJR Am J Roentgenol. 1997;169(2):375–380.
 24. Helbich TH, Heinz-Peer G, Fleischmann D, et al. Evolution of 
CT findings in patients with cystic fibrosis. AJR Am J Roentgenol. 
1999;173(1):81–88.
 25. Santamaria F, Grillo G, Guidi G, et al. Cystic fibrosis: when should high-
resolution computed tomography of the chest be obtained?  Pediatrics. 
1998;101(5):908–913.
 26. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the 
normal maximal expiratory flow-volume curve with growth and aging. 
Am Rev Respir Dis. 1983;127(6):725–734.
 27. Dockery DW, Berkey CS, Ware JH, Speizer FE, Ferris BG Jr. 
Distribution of forced vital capacity and forced expiratory volume 
in one second in children 6 to 11 years of age. Am Rev Respir Dis. 
1983;128(3):405–412.
 28. Kerem E, Reisman J, Corey M, Canny GJ, Levison H.  Prediction 
of mortality in patients with cystic f ibrosis. N Engl J Med. 
1992;326(18):1187–1191.
 29. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of 
inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled 
Tobramycin Study Group. N Engl J Med. 1999;340(1):23–30.
 30. Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of 
oropharyngeal cultures in infants and young children with cystic fibrosis. 
Pediatr Pulmonol. 1999;28(5):321–328.
 31. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, 
Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to 
 identify lower respiratory pathogens in infants with cystic fibrosis. 
Pediatr Pulmonol. 1996;21(5):267–275.
 32. Henig NR, Tonelli MR, Pier MV, Burns JL, Aitken ML. Sputum induc-
tion as a research tool for sampling the airways of subjects with cystic 
fibrosis. Thorax. 2001;56(4):306–311.
 33. Miller MB, Gilligan PH. Laboratory aspects of management of chronic 
pulmonary infections in patients with cystic fibrosis. J Clin Microbiol. 
2003;41(9):4009–4015.
 34. Cantón R, Cobos N, de Gracia J, et al. Antimicrobial therapy for 
pulmonary pathogenic colonisation and infection by  Pseudomonas 
aeruginosa in cystic fibrosis patients. Clin Microbiol Infect. 2005;11(9): 
690–703.
 35. Burns JL, Saiman L, Whittier S, et al. Comparison of agar diffusion 
methodologies for antimicrobial susceptibility testing of Pseudomonas 
aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol. 
2000;38(5):1818–1822.
 36. Saiman L, Burns JL, Whittier S, Krzewinski J, Marshall SA, Jones RN. 
Evaluation of reference dilution test methods for antimicrobial suscepti-
bility testing of Pseudomonas aeruginosa strains isolated from patients 
with cystic fibrosis. J Clin Microbiol. 1999;37(9):2987–2991.
 37. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmo-
nary exacerbation in cystic fibrosis. J Pediatr. 2001;139(3):359–365.
 38. Touw DJ, Vinks AA, Mouton JW, Horrevorts AM.  Pharmacokinetic 
optimisation of antibacterial treatment in patients with cystic fibro-
sis. Current practice and suggestions for future directions. Clin 
 Pharmacokinet. 1998;35(6):437–459.
 39. De Groot R, Smith AL. Antibiotic pharmacokinetics in cystic 
fibrosis. Differences and clinical significance. Clin Pharmacokinet. 
1987;13(4):228–253.
 40. Kirkby S, Novak K, McCoy K. Update on antibiotics for infection control 
in cystic fibrosis. Expert Rev Anti Infect Ther. 2009;7(8):967–980.
 41. Bates RD, Nahata MC, Jones JW, et al. Pharmacokinetics and safety 
of tobramycin after once-daily administration in patients with cystic 
fibrosis. Chest. 1997;112(5):1208–1213.
 42. Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus three-times 
daily regimens of tobramycin treatment for pulmonary exacerbations 
of cystic fibrosis – the TOPIC study: a randomised controlled trial. 
Lancet. 2005;365(9459):573–578.
 43. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with 
intravenous aminoglycosides for cystic fibrosis. Cochrane Database 
Syst Rev. 2010;(1):CD002009.
 44. Rosenfeld M, Ramsey BW, Gibson RL. Pseudomonas acquisition in 
young patients with cystic fibrosis: pathophysiology, diagnosis, and 
management. Curr Opin Pulm Med. 2003;9(6):492–497.
 45. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas 
aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 
1991;338(8769):725–726.
 46. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial 
 colonization with Pseudomonas aeruginosa postpones chronic  infection 
and prevents deterioration of pulmonary function in cystic fibrosis. 
Pediatr Pulmonol. 1997;23(5):330–335.
 47. Stuart B, Lin JH, Mogayzel PJ Jr. Early eradication of Pseudomonas 
aeruginosa in patients with cystic fibrosis. Paediatr Respir Rev. 
2010;11(3):177–184.
 48. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating 
Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane 
Database Syst Rev. 2009;(4):CD004197.
 49. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological 
effect of inhaled tobramycin in young children with cystic fibrosis. Am 
J Respir Crit Care Med. 2003;167(6):841–849.
 50. Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication 
of P. aeruginosa in young children with cystic fibrosis. Eur Respir J. 
2009;33(2):305–311.
 51. Macdonald D, Cuthbertson L, Doherty C, et al. Early Pseudomonas 
aeruginosa infection in individuals with cystic fibrosis: is susceptibility 
testing justified? J Antimicrob Chemother. 2010;65(11):2373–2375.
 52. Moss RB. Long-term benefits of inhaled tobramycin in adolescent 
patients with cystic fibrosis. Chest. 2002;121(1):55–63.
 53. Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic f ibrosis 
 pulmonary guidelines: chronic medications for maintenance of lung 
health. Am J Respir Crit Care Med. 2007;176(10):957–969.
 54. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial 
of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 
2002;20(3):658–664.
 55. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal 
antibiotics for cystic f ibrosis. Cochrane Database Syst Rev. 
2003;3:CD001021.
 56. LiPuma JJ. Microbiological and immunologic considerations with 
aerosolized drug delivery. Chest. 2001;120(3 Suppl):118S–123S.
Infection and Drug Resistance 2011:4submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
40
Sordé et al
 57. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 
1996;42(6):697–705.
 58. Badia JR, Soy D, Adrover M, et al. Disposition of instilled versus 
nebulized tobramycin and imipenem in ventilated intensive care unit 
(ICU) patients. J Antimicrob Chemother. 2004;54(2):508–514.
 59. Guy EL, Bosomworth M, Denton M, Conway SP, Brownlee KG, 
Lee TW. Serum tobramycin levels following delivery of tobramycin 
(Tobi) via eFlow advanced nebuliser in children with cystic fibrosis. 
J Cyst Fibros. 2010;9(4):292–295.
 60. Luyt CE, Clavel M, Guntupalli K, et al. Pharmacokinetics and lung 
delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and 
mechanically ventilated patients with nosocomial pneumonia. Crit Care. 
2009;13(6):R200.
 61. Sexauer WP, Fiel SB. Aerosolized antibiotics in cystic fibrosis. Semin 
Respir Crit Care Med. 2003;24(6):717–726.
 62. McCoy  KS,  Qui t tne r  AL,  Oer mann  CM,  Gibson  RL, 
Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for 
chronic airway  Pseudomonas aeruginosa in cystic fibrosis. Am J Respir 
Crit Care Med. 2008;178(9):921–928.
 63. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety 
of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. 
Chest. 2009;135(5):1223–1232.
 64. Herrmann G, Yang L, Wu H, et al. Colistin–tobramycin combinations are 
superior to monotherapy concerning the killing of biofilm Pseudomonas 
aeruginosa. J Infect Dis. 2010;202(10):1585–1592.
 65. Reed MD, Stern RC, Myers CM, Yamashita TS, Blumer JL. Lack of 
unique ciprofloxacin pharmacokinetic characteristics in patients with 
cystic fibrosis. J Clin Pharmacol. 1988;28(8):691–699.
 66. Ball P. Emergent resistance to ciprofloxacin amongst  Pseudomonas 
aeruginosa and Staphylococcus aureus: clinical significance and 
therapeutic approaches. J Antimicrob Chemother. 1990;26 Suppl F: 
165–179.
 67. Saiman L, Marshall BC, Mayer-Hamblett N, et al.  Azithromycin in patients 
with cystic fibrosis chronically infected with Pseudomonas aeruginosa: 
a randomized controlled trial. JAMA. 2003;290(13):1749–1756.
 68. Peckham DG. Macrolide antibiotics and cystic fibrosis. Thorax. 
2002;57(3):189–190.
 69. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Anti- inflammatory 
effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem 
Biophys Res Commun. 2006;350(4):977–982.
 70. Legssyer R, Huaux F, Lebacq J, et al. Azithromycin reduces  spontaneous 
and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res. 
2006;7:134.
 71. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic 
fibrosis. Cochrane Database Syst Rev. 2004;2:CD002203.
 72. Southern KW, Barker PM. Azithromycin for cystic fibrosis. Eur 
Respir J. 2004;24(5):834–838.
 73. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term  azithromycin 
in children with cystic fibrosis: a randomised,  placebo-controlled cross-
over trial. Lancet. 2002;360(9338):978–984.
 74. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction 
of sputum Pseudomonas aeruginosa density by antibiotics improves 
lung function in cystic fibrosis more than do bronchodilators and 
chest physiotherapy alone. Am Rev Respir Dis. 1990;141(4 Pt 1): 
914–921.
 75. Ramsey BW. Management of pulmonary disease in patients with cystic 
fibrosis. N Engl J Med. 1996;335(3):179–188.
 76. Smith AL, Doershuk C, Goldmann D, et al. Comparison of a  beta-lactam 
alone versus beta-lactam and an aminoglycoside for pulmonary 
 exacerbation in cystic fibrosis. J Pediatr. 1999;134(4):413–421.
 77. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmo-
nary guidelines: treatment of pulmonary exacerbations. Am J Respir 
Crit Care Med. 2009;180(9):802–808.
 78. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. 
Renal impairment in cystic fibrosis patients due to repeated intravenous 
aminoglycoside use. Pediatr Pulmonol. 2005;39(1):15–20.
 79. Elphick HE, Tan A. Single versus combination intravenous antibiotic 
therapy for people with cystic fibrosis. Cochrane Database Syst Rev. 
2005;2:CD002007.
 80. Fernandes B, Plummer A, Wildman M. Duration of intravenous 
 antibiotic therapy in people with cystic fibrosis. Cochrane Database 
Syst Rev. 2008;2:CD006682.
 81. Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home 
 intravenous therapy in cystic fibrosis: a prospective randomized trial 
examining clinical, quality of life and cost aspects. Eur Respir J. 
1997;10(4):896–900.
 82. Balaguer A, González de Dios J. Home intravenous antibiotics for cystic 
fibrosis. Cochrane Database Syst Rev. 2008;3:CD001917.
 83. Braggion C, Cappelletti LM, Cornacchia M, Zanolla L, Mastella G. 
Short-term effects of three chest physiotherapy regimens in patients 
hospitalized for pulmonary exacerbations of cystic fibrosis: a cross-over 
randomized study. Pediatr Pulmonol. 1995;19(1):16–22.
 84. Lambiase A, Raia V, Del Pezzo M, Sepe A, Carnovale V, Rossano F. 
Microbiology of airway disease in a cohort of patients with cystic 
fibrosis. BMC Infect Dis. 2006;6:4.
 85. Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, 
Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant 
Pseudomonas aeruginosa in cystic fibrosis. Chest. 2007;132(2): 
562–568.
 86. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. 
 Outcomes of adults with cystic fibrosis infected with antibiotic-resistant 
Pseudomonas aeruginosa. Respiration. 2006;73(1):27–33.
 87. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of 
intravenous and aerosolized polymyxins for the treatment of infections 
in critically ill patients: a review of the recent literature. Clin Med Res. 
2006;4(2):138–146.
 88. Newton BA. The properties and mode of action of the polymyxins. 
Bacteriol Rev. 1956;20(1):14–27.
 89. Gales AC, Reis AO, Jones RN. Contemporary assessment of 
 antimicrobial susceptibility testing methods for polymyxin B and 
colistin: review of available interpretative criteria and quality control 
guidelines. J Clin Microbiol. 2001;39(1):183–190.
 90. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro 
 pharmacodynamic properties of colistin and colistin methanesulfonate 
against Pseudomonas aeruginosa isolates from patients with cystic 
fibrosis. Antimicrob Agents Chemother. 2001;45(3):781–785.
 91. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the 
management of multidrug-resistant gram-negative bacterial infections. 
Clin Infect Dis. 2005;40(9):1333–1341.
 92. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic 
review of the evidence from old and recent studies. Crit Care. 
2006;10(1):R27.
 93. Parkins MD, Elborn JS. Newer antibacterial agents and their 
 potential role in cystic fibrosis pulmonary exacerbation management. 
J  Antimicrob Chemother. 2010;65(9):1853–1861.
 94. Sahm D. In vitro activity of doripenem. Clin Infect Dis. 2009; 
49 Suppl 1:S11–S16.
 95. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the 
 carbapenems. Drugs. 2007;67(7):1027–1052.
 96. Cirillo I, Vaccaro N, Turner K, Solanki B, Natarajan J, Redman R. 
Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 
1-, and 4-hour infusions in healthy volunteers. J Clin Pharmacol. 
2009;49(7):798–806.
 97. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. 
Efficacy and safety of intravenous infusion of doripenem versus imi-
penem in ventilator-associated pneumonia: a multicenter, randomized 
study. Crit Care Med. 2008;36(4):1089–1096.
 98. Walkty A, Decorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG. 
In vitro activity of ceftobiprole against clinical isolates of Pseudomo-
nas aeruginosa obtained from Canadian intensive care unit (ICU) 
patients as part of the CAN-ICU study. J Antimicrob Chemother. 
2008;62(1):206–208.
Infection and Drug Resistance
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/infection-and-drug-resistance-journal
Infection and Drug Resistance is an international, peer-reviewed open-
access journal that focuses on the optimal treatment of infection (bacte-
rial, fungal and viral) and the development and institution of preventive 
strategies to minimize the development and spread of resistance. The 
journal is specifically concerned with the epidemiology of antibiotic 
resistance and the mechanisms of resistance development and diffusion 
in both hospitals and the community. The manuscript management 
system is completely online and includes a very quick and fair peer-
review system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
41
Management of refractory P. aeruginosa infection in CF
 99. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for 
acute exacerbations in chronic infection of Pseudomonas aeruginosa 
in cystic fibrosis. Cochrane Database Syst Rev. 2008;3:CD006961.
 100. Aaron SD. Antibiotic synergy testing should not be routine for patients 
with cystic fibrosis who are infected with multiresistant bacterial 
organisms. Paediatr Respir Rev. 2007;8(3):256–261.
 101. Holder IA. Pseudomonas vaccination and immunotherapy: an 
 overview. J Burn Care Rehabil. 2001;22(5):311–320.
 102. Lang AB, Rüdeberg A, Schöni MH, Que JU, Fürer E, Schaad UB. 
 Vaccination of cystic fibrosis patients against Pseudomonas  aeruginosa 
reduces the proportion of patients infected and delays time to infection. 
Pediatr Infect Dis J. 2004;23(6):504–510.
 103. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with 
Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst 
Rev. 2008;4:CD001399.
 104. Spiegelberg HL. Biological role of different antibody classes. Int Arch 
Allergy Appl Immunol. 1989;90 Suppl 1:22–27.
 105. Lazar H, Horn MP, Zuercher AW, et al. Pharmacokinetics and safety 
profile of the human anti-Pseudomonas aeruginosa serotype O11 
immunoglobulin M monoclonal antibody KBPA-101 in healthy 
volunteers. Antimicrob Agents Chemother. 2009;53(8):3442–3446.
 106. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. 
Antimicrob Agents Chemother. 2001;45(3):649–659.
 107. McVay CS, Velásquez M, Fralick JA. Phage therapy of Pseudomonas 
aeruginosa infection in a mouse burn wound model. Antimicrob Agents 
Chemother. 2007;51(6):1934–1938.
 108. Watanabe R, Matsumoto T, Sano G, et al. Efficacy of bacterio-
phage therapy against gut-derived sepsis caused by Pseudomonas 
aeruginosa in mice. Antimicrob Agents Chemother. 2007;51(2): 
446–452.
 109. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical 
trial of a therapeutic bacteriophage preparation in chronic otitis due to 
antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of 
efficacy. Clin Otolaryngol. 2009;34(4):349–357.
 110. Veesenmeyer JL, Hauser AR, Lisboa T, Rello J. Pseudomonas 
aeruginosa virulence and therapy: evolving translational strategies. 
Crit Care Med. 2009;37(5):1777–1786.
